Immunome, Inc.IMNMNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank86
3Y CAGR+80.8%
5Y CAGR+80.1%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+80.8%/yr
vs +47.8%/yr prior
5Y CAGR
+80.1%/yr
Consistent
Acceleration
+33.1pp
Accelerating
Percentile
P86
Within normal range
vs 5Y Ago
19x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$218.10M-30.7%
2024$314.84M+154.8%
2023$123.55M+234.8%
2022$36.90M+46.4%
2021$25.20M+119.1%
2020$11.51M+11.2%
2019$10.35M+33.6%
2018$7.74M-